Evidence map›Paper›PMID 24847879›Full record

ArticleNature2014

Cancer biology: Enzyme meets a surprise target.

Marian M Deuker, Martin McMahon

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Marian M DeukerHelen Diller Family Comprehensive Cancer Center and the Department of Cell and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94158, USA.
Martin McMahonHelen Diller Family Comprehensive Cancer Center and the Department of Cell and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94158, USA.

Funding

RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Studying the initiation, progression and therapy of lung cancer in mouse modelsR01CA131261 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2009 to 2026
$5.3M
Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma TherapyR01CA176839 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2013 to 2026
$2.9M
NCI NIH HHS R01 CA131261NCI NIH HHS R01 CA176839NIGMS NIH HHS T32 GM064337
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCell Transformation, NeoplasticHistone-Lysine N-MethyltransferaseHumansLysineMAP Kinase Kinase Kinase 2MAP Kinase Kinase KinasesOncogene Protein p21(ras)Histone-Lysine N-MethyltransferaseLysineMAP3K2 protein, humanMap3k2 protein, mouseMAP Kinase Kinase Kinase 2MAP Kinase Kinase KinasesOncogene Protein p21(ras)SMYD3 protein, humanSmyd3 protein, mouse

Identifiers

PMID24847879
PMCPMC4250228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.